Amgen (AMGN) Change in Receivables (2009 - 2026)

Amgen's Change in Receivables history runs 18 years deep, the most recent figure standing at -$413.0 million for Q1 2026.

• In Q1 2026, Change in Receivables fell 131.57% year-over-year to -$413.0 million; the TTM figure through Mar 2026 stood at $955.0 million (down 29.42% YoY), while the FY2025 annual figure was $2.7 billion, up 706.8% from the prior year.
• Change in Receivables for Q1 2026 stood at -$413.0 million, down from $1.1 billion in the prior quarter.
• The five-year high for Change in Receivables was $1.3 billion in Q1 2025, with the low at -$486.0 million in Q1 2024.
• The 5-year median for Change in Receivables is $180.0 million (2022), against an average of $210.8 million.
• The sharpest annual moves came in 2022 and 2024: Change in Receivables soared 451.79% in 2022, then tumbled 437.5% in 2024.
• Amgen's Change in Receivables stood at $180.0 million in 2022, then surged by 140.56% to $433.0 million in 2023, then tumbled by 209.24% to -$473.0 million in 2024, then jumped by 327.27% to $1.1 billion in 2025, then plunged by 138.42% to -$413.0 million in 2026.
• Business Quant data shows AMGN's Change in Receivables at -$413.0 million in Q1 2026, $1.1 billion in Q4 2025, and -$222.0 million in Q3 2025.